Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from China’s National Medical Products Administration (NMPA) to initiate a Phase Ia clinical trial for its STSP-0902 injection, targeting oligoasthenozoospermia.
The randomized, double-blinded, placebo-controlled study aims to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of STSP-0902 in healthy subjects, with the first patient dosing already completed.
Preclinical findings indicate that STSP-0902, a recombinant human nerve growth factor Fc fusion protein developed in-house, has the potential to enhance nerve growth and promote the proliferation of spermatogonia and testicular Sertoli cells. In mouse models of oligoasthenozoospermia, the treatment has been shown to increase sperm count and motility, reduce the rate of sperm deformities, and mitigate testicular seminiferous tubule degeneration. Additionally, STSP-0902 demonstrated a reduced pain response and a prolonged half-life compared to wild-type human nerve growth factor in preclinical evaluations.- Flcube.com
